Douglas Kiehl

Company: Eli Lilly & Company

Job title: Senior Director Bioproduct Research & Development

Seminars:

Panel Discussion: The Future of HPAPIs, Cost/Risk Analysis & Advanced Manufacturing 10:00 am

As pipelines become more potent, for which indications is costly single nanogram containment cost beneficial for? Contrasting rare disease and wide-spread indications How can we better target drugs to efficaciously apply HPAPI’s for patient benefit? • How are analytical cleaning methods affected, given very low (single particle like) concentrations won’t be distributed like a gas…Read more

day: Day One